119 related articles for article (PubMed ID: 21924262)
1. Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells.
Fiume L; Manerba M; Vettraino M; Di Stefano G
Eur J Pharmacol; 2011 Nov; 670(1):39-43. PubMed ID: 21924262
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
3. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
Manov I; Pollak Y; Broneshter R; Iancu TC
FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
[TBL] [Abstract][Full Text] [Related]
5. Control of cellular proliferation by modulation of oxidative phosphorylation in human and rodent fast-growing tumor cells.
Rodríguez-Enríquez S; Vital-González PA; Flores-Rodríguez FL; Marín-Hernández A; Ruiz-Azuara L; Moreno-Sánchez R
Toxicol Appl Pharmacol; 2006 Sep; 215(2):208-17. PubMed ID: 16580038
[TBL] [Abstract][Full Text] [Related]
6. Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma.
Chiou JF; Tai CJ; Huang MT; Wei PL; Wang YH; An J; Wu CH; Liu TZ; Chang YJ
Ann Surg Oncol; 2010 Feb; 17(2):603-12. PubMed ID: 19830497
[TBL] [Abstract][Full Text] [Related]
7. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.
Chen KF; Chen HL; Tai WT; Feng WC; Hsu CH; Chen PJ; Cheng AL
J Pharmacol Exp Ther; 2011 Apr; 337(1):155-61. PubMed ID: 21205925
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate.
Pereira da Silva AP; El-Bacha T; Kyaw N; dos Santos RS; da-Silva WS; Almeida FC; Da Poian AT; Galina A
Biochem J; 2009 Feb; 417(3):717-26. PubMed ID: 18945211
[TBL] [Abstract][Full Text] [Related]
9. BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma.
Galmiche A; Ezzoukhry Z; François C; Louandre C; Sabbagh C; Nguyen-Khac E; Descamps V; Trouillet N; Godin C; Regimbeau JM; Joly JP; Barbare JC; Duverlie G; Mazière JC; Chatelain D
Mol Cancer Res; 2010 Aug; 8(8):1116-25. PubMed ID: 20647330
[TBL] [Abstract][Full Text] [Related]
10. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
Jane EP; Premkumar DR; Pollack IF
J Pharmacol Exp Ther; 2006 Dec; 319(3):1070-80. PubMed ID: 16959960
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3.
Chen KF; Tai WT; Liu TH; Huang HP; Lin YC; Shiau CW; Li PK; Chen PJ; Cheng AL
Clin Cancer Res; 2010 Nov; 16(21):5189-99. PubMed ID: 20884624
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib down-regulates c-IAP expression post-transcriptionally in hepatic carcinoma cells to suppress apoptosis.
Li XF; Gong RY; Wang M; Yan ZL; Yuan B; Wang K; Shi LH
Biochem Biophys Res Commun; 2012 Feb; 418(3):531-6. PubMed ID: 22285185
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors.
Fiume L; Vettraino M; Manerba M; Di Stefano G
Pharmacol Res; 2011 Apr; 63(4):328-34. PubMed ID: 21168502
[TBL] [Abstract][Full Text] [Related]
14. microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma.
Zhou C; Liu J; Li Y; Liu L; Zhang X; Ma CY; Hua SC; Yang M; Yuan Q
FEBS Lett; 2011 Jun; 585(12):1828-34. PubMed ID: 21530512
[TBL] [Abstract][Full Text] [Related]
15. [RNA biosynthesis in the ascitic cells of Ehrlich's carcinoma and Zajdela's hepatoma under conditions of blocked oxidative phosphorylation].
Shilov LA
Vopr Onkol; 1977; 23(9):55-9. PubMed ID: 198951
[TBL] [Abstract][Full Text] [Related]
16. Oxidative phosphorylation activation is an important characteristic of DOX resistance in hepatocellular carcinoma cells.
Wu L; Zhao J; Cao K; Liu X; Cai H; Wang J; Li W; Chen Z
Cell Commun Signal; 2018 Feb; 16(1):6. PubMed ID: 29402287
[TBL] [Abstract][Full Text] [Related]
17. Effects of Phyllanthus urinaria extract on HepG2 cell viability and oxidative phosphorylation by isolated rat liver mitochondria.
Chudapongse N; Kamkhunthod M; Poompachee K
J Ethnopharmacol; 2010 Jul; 130(2):315-9. PubMed ID: 20488238
[TBL] [Abstract][Full Text] [Related]
18. The different induction mechanisms of growth arrest DNA damage inducible gene 45 β in human hepatoma cell lines.
Seewoo V; Yang W; Du H; Wang J; Lin A; Shen B; Peng C; Li H; Qiu W
Chemotherapy; 2012; 58(2):165-74. PubMed ID: 22678405
[TBL] [Abstract][Full Text] [Related]
19. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
20. Interaction of Na+ and K+ transport with aerobic energy metabolism in slices of Morris hepatoma 3924A.
Galeotti T; van Rossum GD; Russo MA; Palombini G
Cancer Res; 1976 Nov; 36(11 Pt 1):4175-84. PubMed ID: 184927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
